Keyphrases
MHC Class II Deficiency
100%
RFX5
100%
Multicenter Cohort
100%
Clinical Genetics
100%
RFXANK
80%
Gene mutation
60%
Patient Outcomes
40%
Hematopoietic Stem Cell Transplantation
40%
Survival Rate
20%
Turkey
20%
Cell Surface
20%
Retrospective Analysis
20%
Overall Survival Rate
20%
Pneumonia
20%
Specific Genes
20%
Late-onset
20%
Late Diagnosis
20%
Survival Analysis
20%
Prognostic Indicator
20%
Founder Effect
20%
Immunological Profile
20%
Early Diagnosis
20%
CD8+ T
20%
Antigen-presenting Cells
20%
Clinical Profile
20%
Combined Immunodeficiency
20%
Immune Parameters
20%
Cell Count
20%
Severe Infection
20%
Blood Cells
20%
MHC Class II
20%
Major Histocompatibility Complex Class II Deficiency
20%
Early Prognosis
20%
HLA Class II
20%
Persistent Diarrhea
20%
Infection History
20%
Genetic Profile
20%
CIITA
20%
RFXAP
20%
Early Death
20%
Diagnostic Delay
20%
Biochemistry, Genetics and Molecular Biology
MHC Class II
100%
RFX5
100%
RFXANK
80%
Gene Mutation
60%
Survival Rate
40%
Hematopoietic Stem Cell Transplantation
40%
Major Histocompatibility Complex
20%
Prevalence
20%
Founder Effect
20%
Overall Survival
20%
Immunocompetent Cell
20%
CD8 Lymphocyte Count
20%
Antigen Presenting Cell
20%
CIITA
20%
Immunology and Microbiology
Bare Lymphocyte Syndrome
100%
Gene Mutation
50%
Survival Rate
33%
Hematopoietic Stem Cell Transplantation
33%
Combined Immunodeficiencies
16%
Prevalence
16%
Overall Survival
16%
Immunocompetent Cell
16%
Antigen-Presenting Cell
16%
CIITA
16%
Founder Effect
16%
CD8 Lymphocyte Count
16%